Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
1.115
-0.025 (-2.19%)
At close: Nov 6, 2025, 4:00 PM EST
1.130
+0.015 (1.35%)
After-hours: Nov 6, 2025, 8:00 PM EST
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
4.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
| Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
| Dec 31, 2021 | 86.99K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OGEN News
- 16 days ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 4 weeks ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire
- 3 months ago - Oragenics Q2 2025 Shareholder Update - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - GlobeNewsWire
- 4 months ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 6 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire
- 6 months ago - Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision - GlobeNewsWire